Turgut AKSOY
(Bezmialem Vakıf Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, İstanbul, Türkiye)
Didem Can TRABLUS
(Sağlık Bilimleri Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, İstanbul, Türkiye)
Hale ARAL
(Sağlık Bilimleri Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya Laboratuvarı Kliniği, İstanbul, Türkiye)
Erdinç SERİN
(İstanbul Şişli Hamidiye Eftal Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya Laboratuvarı Kliniği, İstanbul, Türkiye)
Canan Kelten TALU
(Sağlık Bilimleri Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Klinik Patoloji Laboratuvarı Kliniği, İstanbul, Türkiye)
Yıl: 2020Cilt: 21Sayı: 5ISSN: 2619-9793 / 2148-094XSayfa Aralığı: 355 - 361İngilizce

62 0
Significantly Lower Serum Adiponectin Levels in the Postmenopausal Age may be Specific for Breast Cancer Risk
Introduction: To date, biomarkers have played a minimal role in the early diagnosis of breast cancer. Although its effects on metabolism are not well known, studies have shown that hypoadiponectinaemia is associated with increased insulin resistance and risk for type-2 diabetes. We aimed to investigate the value of adiponectin together with laboratory results, anthropometric measurements and histopathological findings in assessing the risk of breast cancer and for use in early diagnosis.Methods: In this study, serum samples were obtained from 59 recently diagnosed breast cancer patients and 47 cancer-free controls aged between 22 and 82 years to assay serum adiponectin, lipids, fasting blood glucose and insulin; homeostatic model assessment for insulin resistance (HOMA-IR) and body mass index were calculated using the anthropometric measurements. Histopathologic findings were extracted from the patients’ files.Results: Our results revealed that adiponectin serum levels and HOMA-IR values were significantly different between patients and controls. In addition, serum adiponectin levels were lower in postmenopausal breast cancer patients compared to the controls (p=0.03).Conclusion: In fact, a serum adiponectin level below 4.46 mg/L may be in favour of postmenopausal breast cancer (area under the curve =70%). However, Cerb-B2 expression in patients did not correlate with serum adiponectin levels. These findings have implications for further research on adiponectin as well as the in early diagnosis of postmenopausal breast cancer with possibly higher test sensitivity.
DergiAraştırma MakalesiErişime Açık
  • 1. WHO incidence. [Online] Available from: URL: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/.
  • 2. GLOBOCAN 2008. [Online] Available from URL: https://www.iarc.fr/wp-content/uploads/2018/07/GLOBOCAN2008.pdf.
  • 3. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, Comparative risk assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors Lancet 2005; 366; 1784-93.
  • 4. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
  • 5. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009; 20: 193-201.
  • 6. Dalamaga M. Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets. World J Exp Med 2013; 3: 34-42.
  • 7. Avgerinos K, Spyrou N, Mantzoros C, Dalamaga M. Obesity and Cancer Risk: Emerging biological mechanisms and perspective. Metabolism 2019; 92: 121-35.
  • 8. Spyrou N., Avgerinos K., Mantzoros C., Dalamaga M. Classic and novel adipocytokines at the intersection of obesity and cancer: diagnostic and therapeutic strategies. Curr Obes Rep 2018; 7: 260-75.
  • 9. Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U, Alomeroglu M. Tissue levels of adiponectin in breast cancer patients. Med Oncol 2007; 24: 361-6.
  • 10. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006; 237: 109-14.
  • 11. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 1102-7.
  • 12. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92: 1041-8.
  • 13. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer. Endocr Rev 2012; 33: 547-94.
  • 14. Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007; 167: 2091-102.
  • 15. Emaus MJ, van Gils CH, Bakker MJ, Bisschop CNS, Monninkhof EM, de Mesquita HBB, et al. Weight change in middle adulthood and breast cancer risk in the EPIC‐PANACEA study. Int J Cancer 2014; 135: 2887-99.
  • 16. Rosner B, Eliassen AH, Toriola AT, Chen WY, Hankinson SE, Willett WC, et al. Weight and weight changes in early adulthood and later breast cancer risk. Int J Cancer 2017; 140: 2003-14.
  • 17. Chen Y, Liu L, Zhou Q, Imam MU, Cai J, Wang Y, et al. Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response meta-analysis with 3,318,796 subjects from 31 cohort studies. BMC Public Health 2017; 17: 936.
  • 18. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine 2010; 37: 11-32.
  • 19. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker Best Pract Res Clin Endocrinol Metab 2014 ; 28: 119-30.
  • 20. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agostino sr RB, Wilson PWF, et al. Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance J Clin Endocrinol Metab 2008; 93: 3165-72.
  • 21. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
  • 22. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-26.
  • 23. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, Rinaldi S, Scarmo S, Liu M, et al. Premenopausalserum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res 2012; 14: R32.
  • 24. Cubukcu E, Olmez F, Kanat O, Kabul S, Canhoroz M, Avci N, et al. Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer Contemp Oncol (Pozn) 2014; 18: 34-8.
  • 25. Gu L, Cao C, Fu J, Li Q, Li DH, Chen MY. Serum adiponectin in breast cancer: A meta-analysis. Medicine (Baltimore) 2018; 97: e11433.
  • 26. Ma HQ, Cui LH, Li CC, Yu Z, Piao JM. Effects of Serum Triglycerides on prostate cancer and breast cancer risk: a meta-analysis of prospective studies. Nutr Cancer 2016; 68: 1073-82.
  • 27. Li X, Liu Z, Wu H, Dai W, Arshad B, Xu Z, et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis 2018; 17: 91.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.